Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial (TALENT Study) of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen (control) at 48-week in treatment experienced HIV-1 infected adults. In addition, patients administered with albuvirtide showed statistically better renal safety than those taking the control regimen containing tenofovir disoproxil fumarate.

Published
07 June 2016
From
Frontier Biotech press release
HIV and drug resistance

A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

Published
09 February 2016
From
UNAIDS
People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs

HIV-positive patients who are taking a large number of medications for the treatment of non-HIV-related conditions are at increased risk of stopping or changing their antiretroviral therapy (ART),

Published
27 January 2016
By
Michael Carter
Undetectable & Low-level HIV Viral Replication

Even people who are adherent to their medication regimens may experience occasional “blips” in their viral loads, experience viral rebound or maintain a steady, if low, viral load above undetectable levels. To understand why some people struggle to achieve or remain undetectable, we spoke with Keith Henry, MD, an HIV specialist at Hennepin County Medical Center who has more than 25 years of experience caring for people with HIV.

Published
06 January 2016
From
BETA blog
Study: Protease Inhibitor Monotherapy Does Not Limit Future Treatment Options

A recent study published in The Lancet HIV provides evidence that HIV maintenance therapy with a provider-selected boosted protease inhibitor (PI) regimen does not increase the risk of drug resistance and thus preserves future treatment options. But questions remain as to whether PI-monotherapy could be a clinically useful and relevant long-term HIV maintenance strategy.

Published
10 December 2015
From
BETA blog
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART

Two-drug antiretroviral therapy (ART) consisting of ritonavir-boosted atazanavir and lamivudine has comparable or better virological efficacy than traditional three-drug therapy based on ritonavir/atazanavir, according to a poster presentation at

Published
30 November 2015
By
Michael Carter
Study shows effectiveness of switching antiretroviral therapy for HIV-infected children

A Columbia University study evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than three years, without risk of viral failure. The researchers reported that the treatment program resulted in excellent sustained virological control.

Published
06 November 2015
From
Eurekalert Inf Dis
Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety

A single-tablet regimen containing the new tenofovir alafenamide (TAF) – to be marketed as Genvoya – suppressed HIV as well as a co-formulation containing the older tenofovir

Published
25 October 2015
By
Liz Highleyman
Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?

The potent integrase inhibitor dolutegravir taken with a single well-tolerated NRTI was able to fully suppress viral load in people initiating antiretroviral treatment for the first time, while

Published
23 October 2015
By
Liz Highleyman
British HIV Association (BHIVA) 2015 Treatment Guidelines published

The new BHIVA treatment guidelines recommend: "All individuals with HIV... are reviewed promptly by an HIV specialist and offered immediate ART." See http://www.aidsmap.com/page/2979458/ for a summary of the main recommendations.

Published
26 September 2015
From
BHIVA
← First12345...26Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close